Objectives
toxicity, tumor
TUMOR
The primary objective was to assess the safety and tolerability of DS-1205c in combination with osimertinib in metastatic or unresectable Secondary objectives included: preliminary evaluation of the antitumor efficacy of DS-1205c plus osimertinib, and characterization of the PK profile of DS-1205a following DS-1205c monotherapy and in combination with osimertinib. Exploratory objectives included identifying biomarkers or levels of AXL-positivity in tumor cells that correlate with the treatment response or toxicity.